What Is CBG? The Complete Guide to Cannabigerol

CBG's mechanism of action is more complex than CBD's. While CBD has low binding affinity for CB1 and CB2 receptors and works primarily through indirect pathways, CBG acts as a partial agonist at both CB1 and CB2 receptors — meaning it binds to and activates them, but with less intensity than THC.

This partial agonism gives CBG a unique pharmacological profile. At CB1 receptors (concentrated in the brain and central nervous system), CBG exerts a mild modulatory effect that may counterbalance THC's psychoactivity without producing intoxication of its own. At CB2 receptors (more abundant in immune cells and peripheral tissues), CBG's activation is thought to drive its anti-inflammatory effects.

CBG also interacts with several non-cannabinoid receptors. It is a potent agonist of the alpha-2 adrenoceptor, which is involved in pain modulation and blood pressure regulation. It inhibits GABA reuptake, which may contribute to its anxiolytic and muscle-relaxant effects. And unlike CBD, CBG activates TRPV1 and TRPV2 channels — the same receptors targeted by capsaicin — which may be relevant to its pain-relieving properties.

The key difference from CBD: where CBD is an allosteric modulator that tweaks how other cannabinoids bind, CBG is a direct actor at multiple receptor sites. This may explain why some users report more noticeable effects from CBG than from CBD, particularly in terms of focus, energy, and anti-inflammatory relief.

The research on CBG is early but promising. Most findings come from preclinical studies — animal models and in vitro assays — with human clinical trials only just beginning. Here is what the current evidence suggests:

Anti-Inflammatory

CBG has demonstrated potent anti-inflammatory effects across multiple studies. A 2024 animal model of inflammatory bowel disease found that CBG reduced colonic inflammation and improved disease activity scores more effectively than CBD at equivalent doses. The effect is mediated through CB2 receptor activation and inhibition of pro-inflammatory cytokines like TNF-alpha and IL-6.

Neuroprotection

Preclinical research indicates CBG may have neuroprotective properties relevant to conditions like Huntington's disease and multiple sclerosis. A 2023 study in a mouse model of Huntington's found that CBG improved motor function and reduced oxidative stress in brain tissue. The compound appears to promote neurogenesis and protect neurons from glutamate-induced excitotoxicity.

Appetite Stimulation

Unlike CBD (which is appetite-neutral), CBG appears to stimulate appetite in animal studies. A 2022 study found that CBG increased food intake and meal frequency in rats compared to controls, without the hyperphagia associated with THC. This has potential applications for cachexia, chemotherapy patients, and eating disorders, though human data is needed.

Glaucoma and Intraocular Pressure

CBG is a potent vasodilator and has been shown to reduce intraocular pressure (IOP) in animal models — an effect relevant to glaucoma management. A 2023 rabbit model study found that topical CBG reduced IOP by 20-25% within two hours, comparable to THC but without psychoactive side effects. Human studies are in early stages.

Antibacterial

CBG has demonstrated broad-spectrum antibacterial activity, including against MRSA (methicillin-resistant Staphylococcus aureus). A 2020 study found that CBG was effective against drug-resistant bacteria at concentrations comparable to established antibiotics, and that it worked synergistically with polymyxin B. This is particularly exciting given the global crisis of antibiotic resistance.

The research pipeline for CBG is accelerating. As of 2026, there are approximately 15 active or recently completed clinical trials investigating CBG or CBG-dominant formulations — up from just 3 in 2021.

What We Know

We know CBG is safe and well-tolerated in humans. Phase I safety trials have established that single oral doses up to 200mg and repeated doses up to 100mg daily for 28 days produce no serious adverse effects. The most common side effects are mild — dry mouth, drowsiness, and slight dizziness — and comparable to those of CBD.

We also know CBG has good oral bioavailability when formulated with lipid carriers (MCT oil, nano-emulsions). A 2024 pharmacokinetic study found that water-dispersible CBG achieved peak plasma concentrations within 1-2 hours of administration, with a half-life of approximately 6-8 hours.

What We Don't Know

Human efficacy data is still thin. Most claims around CBG's therapeutic benefits — neuroprotection, glaucoma, appetite stimulation — are based on animal studies that may not translate to humans. Only a handful of small human trials have been completed, and none have been large enough to draw definitive conclusions.

We also don't know the optimal dosing range for specific conditions, the long-term safety profile beyond 28 days, or how CBG interacts with common medications. Drug-drug interaction studies (particularly with CYP450-metabolised drugs like warfarin, SSRIs, and antiepileptics) have not been conducted for CBG as they have for CBD.

The evidence gap is narrowing but real. CBG shows genuine therapeutic promise, but it is not yet evidence-based medicine in the way that, say, CBD for epilepsy or THC for chemotherapy-induced nausea is. Anyone considering CBG for a medical condition should treat it as a supplement with suggestive preclinical data, not a proven treatment.

CBG is available in several forms in the UK market, though the selection is narrower than for CBD. Here is what you need to know about products, dosing, and combining with other cannabinoids:

Products Available

CBG oils and tinctures are the most common form, typically sold as broad-spectrum extracts containing CBG alongside CBD and trace amounts of other cannabinoids. Pure CBG isolate (99%+ CBG in crystalline powder form) is also available for those who want to avoid any THC or CBD. CBG capsules, gummies, and vape cartridges are less common but growing in availability. Flower and hash with elevated CBG content (5-15%) are available through medical cannabis channels and some CBD retailers.

Dosing

CBG is more potent per milligram than CBD, so start lower. A typical starting dose is 10-20mg of CBG taken once or twice daily. Experienced users may go up to 50-100mg per day, but there is little evidence that doses above 100mg provide additional benefit. Because CBG is fat-soluble, take it with a meal containing healthy fats (avocado, olive oil, nuts) to improve absorption.

Combining with CBD

Many users find CBG and CBD work better together than either alone — the 'entourage effect' in action. A common approach is a 1:1 ratio (e.g., 20mg CBG + 20mg CBD) or a 2:1 CBD:CBG ratio for daytime use. CBG is often described as more energising and focus-promoting than CBD, making it a better choice for morning and afternoon use, while CBD alone may be preferred for evening relaxation.

Combining with THC

CBG appears to moderate some of THC's psychoactive effects. A 2025 survey study found that users who consumed CBG alongside THC reported less anxiety and paranoia than those taking THC alone. Some medical cannabis strains bred for elevated CBG (like 'White CBG' and 'Super Glue CBG') are marketed specifically for this balancing effect.

CBG occupies the same legal territory as CBD under UK law. Under the Misuse of Drugs Act 1971 and the 2018 Home Office guidance on cannabidiol, cannabinoids derived from industrial hemp (Cannabis sativa L.) are legal to possess, sell, and consume as long as they meet three conditions: they contain less than 0.2% THC, they are not advertised as medicinal products without a Medicines and Healthcare products Regulatory Agency licence, and they are not controlled substances in their own right.

CBG is not listed as a controlled substance under Schedule 1 or 2 of the Misuse of Drugs Regulations 2001. However, CBG products derived from cannabis plants with a THC content above 0.2% would be illegal under UK law, regardless of their CBG content. This is why reputable CBG brands in the UK use EU-certified industrial hemp varieties with THC levels reliably below the legal threshold.

The Food Standards Agency has not issued specific novel food guidance for CBG as it has for CBD. As of 2026, CBG is generally treated as a novel food ingredient that requires authorisation before it can be marketed as a food supplement. Most UK CBG products are currently sold as 'cosmetic-grade' or 'non-consumable' items, or under the CBD novel food authorization umbrella by brands that have included CBG in their submissions.

For medical cannabis patients in the UK, CBG-rich flower and oils are available by prescription through specialist clinics. Products like 'CBG Goddess' and 'CBG Platinum' are listed on formularies at clinics including Sapphire, Curaleaf, and Cantourage. Patients considering CBG should discuss it with their specialist, particularly if they are already prescribed THC-containing products.